438187

Lovastatin, Sodium Salt

InSolution ≥95%

• Synonym(s): InSolution Lovastatin, Sodium Salt
• Empirical Formula (Hill Notation): C₂₄H₃₇O₆ · Na
• Molecular Weight: 444.54
• UNSPSC Code: 51111800
• NACRES: NA.77

Properties

• Quality Level: 100
• assay: ≥95% (HPLC)
• form: liquid
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze; avoid repeated freeze/thaw cycles; protect from light
• shipped in: dry ice
• storage temp.: −70°C

Description

General description

Carboxylate form of Lovastatin (Cat. No. 438185) that is active in whole cells and cell-free assays. Lovastatin is reported to be an anti-hypercholesterolemic agent that acts as a reversible competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and blocks a series of biological events including activation of p21^ras by insulin in 3T3-L1 fibroblasts and 3T3-L1 adipocytes, farnesylation of p21^ras, which decreases the pool of intracellular Ras available for subsequent activation by growth factors (including insulin), and N-ras-induced neuronal differentiation. Causes cell cycle arrest in the late G1 phase. Shown to inhibit the stimulation of MAP kinase by insulin in HIRcB cells and block the transcription of the type-I SCR gene in THP-1-derived macrophages. Also blocks PDGF receptor tyrosine phosphorylation and MAP kinase activation by PDGF.

Carboxylate form of Lovastatin (Cat. No. 438185) that is active in whole cells and cell-free assays. Lovastatin is reported to be an anti-hypercholesterolemic agent that acts as a reversible competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and blocks a series of biological events including activation of p21^ras by insulin in 3T3-L1 fibroblasts and 3T3-L1 adipocytes, farnesylation of p21^ras, which decreases the pool of intracellular Ras available for subsequent activation by growth factors (including insulin), and N-ras-induced neuronal differentiation. Causes cell cycle arrest in the late G1 phase. Shown to inhibit the stimulation of MAP kinase by insulin in HIRcB cells and block the transcription of the type-I SCR gene in THP-1-derived macrophages. Also blocks PDGF receptor tyrosine phosphorylation and MAP kinase activation by PDGF.

Biochem/physiol Actions

Cell permeable: yes

Primary Target
HMG-CoA reductase

Reversible: yes

Packaging

Packaged under inert gas

Warning

Toxicity: Harmful (C)

Physical form

A 10 mM (5 mg/1.13 ml) solution of Lovastatin, Sodium Salt (Cat. No. 438186) in H₂O.

Reconstitution

Following initial thaw, aliquot and freeze (-70°C). Aliquots are stable for up to 6 months at -70°C.

Other Notes

Rao, S., et al. 1999. Proc. Natl. Acad. Sci. USA96, 7197.
Carel, K., et al. 1996. J. Biol. Chem.271, 30625.
McGuire, T.F., et al. 1996. J. Biol. Chem.271, 27402.
Umetani, N., et al. 1996. Biochim. Biophys. Acta1303, 199.
Xu, X.Q., et al. 1996. Arch. Biochem. Biophys.326, 233.
Reusch, J.E.-B., et al. 1995. J. Biol. Chem.270, 2036.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Safety Information

• Storage Class: 12 - Non Combustible Liquids
• wgk_germany: nwg
• flash_point_f: Not applicable
• flash_point_c: Not applicable